Euretina Congress

VIENNA ― At the Euretina meeting here, Jay Chhablani, MD, discusses safety results of a large cohort of patients with diabetic macular edema treated with Ozurdex (dexamethasone intravitreal implant, Allergan).

VIENNA — At the Euretina meeting, Marc de Smet, MD, PhD, speaks about the use of biologics in uveitis and gives pearls on indications, contraindications and treatment schemes.

VIENNA — At the Euretina meeting, Hemal Mehta, MD, speaks about the early results of the PanOptica clinical trial on a new molecule for the topical treatment of age-related macular degeneration, which could revolutionize the way the disease is treated.

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, according to a specialist reporting on the Euretina guidelines for the management of retinal disease.

VIENNA — There is no reason to be afraid of using a heads-up 3-D viewing modality to perform surgery because the advantages are immediately appreciated when surgeons try it, according to one specialist.

VIENNA — At the Euretina meeting, Catharina Busch, MD, discusses the results of a study showing patients with diabetic macular edema who do not respond to an anti-VEGF loading dose may benefit from dexamethasone steroid treatment with the Ozurdex (Allergan) implant.

VIENNA ― Javier Zarranz-Ventura, MD, PhD, discusses his presentation at the Euretina meeting in which he reviewed the use of OCT to observe cytokine changes in patients treated with anti-VEGF as well as steroids for diabetic macular edema.

VIENNA — Ninety-six-week outcomes of the ALTAIR study demonstrated safety and efficacy of treat-and-extend aflibercept administration with both 2-week and 4-week adjustments in patients with wet AMD. The study involved 255 patients treated at 40 sites in Japan.

VIENNA — Real-world 3-year data from the RETRO-IDEAL study showed that advanced diabetic macular edema cases can benefit from being treated with the Iluvien fluocinolone acetonide intravitreal implant from Alimera Sciences. The study was a retrospective analysis of 100 patients treated in Germany and consisted of two groups, vitrectomized and non-vitrectomized eyes.

VIENNA — At the Euretina meeting, José García-Arumi, MD, PhD, gives highlights on the latest advancements in retina, including pharmacology, 3-D surgery, intraoperative OCT, hypersonic vitrectomy and new surgical techniques.